• Explore /
  • Poster
  • / RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced <em>KRAS</em> G12V mutant non–small cell lung cancer (NSCLC).

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Abstract Poster

Authors

Joshua Reuss

Joshua E. Reuss

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Joshua E. Reuss , Sunil G. Gandhi , David R. Spigel , Pasi A. Janne , Luis G. Paz-Ares , Shirish M. Gadgeel , Jyoti D. Patel , Francesco Passiglia , Alexander I. Spira , Martin Joseph Edelman , George R. Blumenschein , Ardaman Shergill , Timothy F. Burns , Vijeta Bhambhani , Gloria Patrick , Jonathan A. Pachter , Louis J. Denis , D. Ross Camidge

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04620330

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9100)

DOI

10.1200/JCO.2023.41.16_suppl.9100

Abstract #

9100

Poster Bd #

88

Abstract Disclosures

Similar Posters

First Author: Ramaswamy Govindan

First Author: Susana N. Banerjee

First Author: Susana N. Banerjee

First Author: Sukhmani Kaur Padda